HSP90AA1 and neoplasm: Thus, HSP90/AXL/eIF4E-regulated UPR that underpins adaptive resistance to MTA and trametinib also regulates intratumor heterogeneity of KRAS-mutant lung tumor cells that occurs under pathological conditions, extrapolating our findings to a generalized principle that governs tumor progression (Fig. 4a).